Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT01889095

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01889095
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01889095. Randomized; single masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2011-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients
Condition
Diabetes Type 2
Intervention (Drug)
BIAsp 30
Intervention (Drug)
NPH/Reg
Lead sponsor
Tehran University of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct01889095
Content hash
76203508cfb87ea3955988d1bdc75bfe74751d7d8766dd6e83d5283bff221512